Immunome, Inc.
NCM: IMNMLive Quote
📈 ZcoreAI Score
Our AI model analyzes Immunome, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get IMNM Z-Score →About Immunome, Inc.
Healthcare
Biotechnology
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
📊 Fundamental Analysis
Immunome, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -52.1%, which indicates that capital utilization is currently under pressure.
At a current price of $21.67, IMNM currently sits at the 71st percentile of its 52-week range (Range: $6.96 - $27.65).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$2.45B
Trailing P/E
--
Forward P/E
-10.25
Beta (5Y)
2.14
52W High
$27.65
52W Low
$6.96
Avg Volume
1.45M
Day High
Day Low